Completion of £8.75 million Fundraising

Verici Dx PLC

13 October 2026

 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

13 October 2026

Verici Dx plc

(“Verici Dx” or the “Company”) 

Completion of £8.75 million Fundraising
Restoration of Trading on AIM

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, has today announced that the Company has raised £8.75 million through the Placing announced on 8 October 2026 and the WRAP Retail Offer launched on 9 October 2026.

Following closing of the Fundraising, the Company is pleased to announce that the Capital Access Window has closed, and that trading of the Company’s Ordinary Shares on AIM will be restored with effect from 7:30am today.

Enquiries:

Verici Dx plc	www.vericidx.com
Sara Barrington, CEO	Via Walbrook PR
Julian Baines, Chairman
Singer Capital Markets (Nominated Adviser, Joint Broker & Joint Bookrunner)		Tel: [phone]
Russell Cook / Anastassiya Eley / Harry Littlewood
Oberon Capital (Joint Broker & Joint Bookrunner)	Tel: [phone]
Mike Seabrook / Heena Karani
Walbrook PR (Media & Investor Relations)	Tel: [phone] or [e-mail]
Alice Woodings / Rachel Broad	Mob: [phone]

About Verici Dx plc www.vericidx.com

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk, to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure, from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

 

END